MANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of ...

MANILA, Philippines — The Court of Appeals (CA) has denied the French drugmaker Sanofi Pasteur Inc ... for its controversial dengue vaccine, Dengvaxia. In a resolution dated Sept.

The first launch was in the Philippines ... programme was rushed, while Sanofi Pasteur representatives stood by the safety and efficacy of Dengvaxia. In the meantime, Sanofi held an analyst ...

MANILA, Philippines — The Court of Appeals (CA) has denied the motion for reconsideration filed by French drugmaker Sanofi ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one of the world’s largest producers of vaccinations for a variety of conditions, including tetanus ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and drug shortages have prompted a call for industrial action in the company ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

MANILA, Philippines — Despite a motion by defense lawyers to stay put, a Quezon City trial court judge decided to inhibit himself from further handling the second batch of 35 Dengvaxia cases. Judge ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...